Anti-inflammatory therapy cuts risk of lung cancer

In most clinical trials for cancer therapy, investigators test treatments in patients with advanced disease. But a recent cardiovascular secondary prevention study has given researchers a unique opportunity: to explore the effectiveness of giving a drug to patients before cancer emerges. At the European Society of Cardiology meeting, Paul M. Ridker, MD, director of the Center for Cardiovascular Disease Prevention at BWH, and colleagues presented findings from CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Related Links:

Conclusions: Advanced lung cancer patients on platinum chemotherapy are predisposed to thromboembolism due to many factors. Despite its lower incidence in our study, exclusion of patients with prior thrombosis suggests the incidence of de novo thrombosis, and hence raises a valid question of the need of thromboprophylaxis in a selected group of patients. PMID: 30483356 [PubMed]
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
This report highlights the occurrence of rapid progression of lung cancer following delivery that led to postpartum acute respiratory failure, rather than due to pulmonary thromboembolism associated with the existing deep venous thrombosis of the inferior vena cava. PMID: 30449778 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
IntroductionPatients with cancer commonly present with laboratory evidence of hypercoagulability. The HYPERCAN study (ClinicalTrials.gov, ID# NCT02622815) is an ongoing Italian prospective, multicenter, observational study, evaluating the predictive value of thrombotic markers for early cancer diagnosis in healthy subjects and for cancer prognosis and venous thromboembolism in patients with newly diagnosed cancer disease (Thromb Res, 2016).In this analysis of the HYPERCAN study, in a subcohort of consecutive patients with newly diagnosed metastatic non-small cell lung (NSCL) or gastrointestinal (GI) cancers, we aimed to as...
Source: Blood - Category: Hematology Authors: Tags: 331. Pathophysiology of Thrombosis: Poster III Source Type: research
ConclusionThese studies demonstrate that exosomes derived from both primary, non-transformed cells (HDF), as well as cancer cell lines have the ability to support FXII autoactivation in human plasma. Their ability to do is proportional to the relative risk of thrombosis associated with cancers derived from their parental cell lines. Treatment of exosomes with CIP substantially reduces the FXII activating capacity of those derived from the tested cancer cell lines and HDF. Human plasma exosomal PP is a constitutive potential source for contact activation that may be increased in cancer patients. Its relative contribution to...
Source: Blood - Category: Hematology Authors: Tags: 331. Pathophysiology of Thrombosis: Poster III Source Type: research
ConclusionsDOACs can be safely administered to patients with brain tumors. In patients with primary brain tumors (i.e. glioma), DOACs appear to be safer than LMWH and should be considered for this indication.Figure.DisclosuresZwicker: Incyte: Research Funding; Parexel: Consultancy; Quercegen: Research Funding; Daiichi: Honoraria.
Source: Blood - Category: Hematology Authors: Tags: 332. Antithrombotic Therapy: Poster II Source Type: research
Conclusions: This single-center study suggests that a higher proportion of Black cancer patients exhibited cancer-associated VTE compared to White cancer patients. Importantly, this significant difference was especially reflected in specific cancer subtypes. Race had an independent effect on cancer-associated VTE but showed no significant influence on recurrent VTE. Our current investigation motivates additional large-scale studies of cohorts with substantial representation of Blacks and ethnic minorities to further identify factors that contribute to racial disparities in the context of cancer-associated VTE, thus guiding...
Source: Blood - Category: Hematology Authors: Tags: 903. Outcomes Research-Non-Malignant Hematology: Health Outcomes in Hemophilia, Thrombosis, ITP, and Hereditary Transthyreitin Amyloidosis Source Type: research
Conclusion: We found that in patients undergoing anatomic resection for primary lung cancer, the blood transfusion and chest drain volume did not differ whether the patients were given enoxaparin or not. To our knowledge, the impact on chest drain volume of Low-Molecular-Weight Heparin given to anatomic resection patients with non-small cell lung carcinoma has not been investigated before.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
Conclusions: High-risk Khorana score may represent an independent predictor of reduced survival in lung adenocarcinoma patients receiving first line or adjuvant chemotherapy.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
PMID: 30449246 [PubMed - as supplied by publisher]
Source: Phlebology - Category: Internal Medicine Authors: Tags: Phlebology Source Type: research
Conclusion Even on the basis of adequate mechanical prophylaxis, lower limb DVT is common in severe patients after thoracic surgery. Meanwhile, male patients and malignant diseases are more suscepted. 
 DOI: 10.3779/j.issn.1009-3419.2018. 11.12
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular | Clinical Trials | Heart | Lung Cancer | Pharmaceuticals | Study | Thrombosis